Research News

Starting long acting bronchodilators for COPD is associated with increased cardiovascular risk, finds study

BMJ 2018; 360 doi: (Published 03 January 2018) Cite this as: BMJ 2018;360:k11
  1. Susan Mayor
  1. London

Initiating treatment of chronic obstructive pulmonary disease (COPD) with a long acting β2 agonist or a long acting antimuscarinic antagonist is associated with a 50% higher risk of serious cardiovascular events, including in patients with no previous cardiovascular disease, a large case-control study has found.1

Inhaled long acting bronchodilators are the standard treatment for COPD, and data on cardiovascular risk has been mixed.

Researchers used data from the Taiwan National Health Insurance …

View Full Text

Log in

Log in through your institution


* For online subscription